Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02IMK
|
|||
| Former ID |
DNC013933
|
|||
| Drug Name |
FGGFTGARKSARKRKRK
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C85H147N33O20
|
|||
| Canonical SMILES |
CC(C(C(=O)NCC(=O)NC(C)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCCN)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCCN)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCCN)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCCN)C(=O)O)NC(=O)C(CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)C(CC2=CC=CC=C2)N)O
|
|||
| InChI |
1S/C85H147N33O20/c1-48(106-65(122)46-105-80(136)67(50(3)120)118-78(134)62(43-52-24-8-5-9-25-52)108-66(123)45-103-64(121)44-104-70(126)53(90)42-51-22-6-4-7-23-51)68(124)109-57(30-18-38-99-82(91)92)73(129)113-56(28-12-16-36-88)77(133)117-63(47-119)79(135)107-49(2)69(125)110-58(31-19-39-100-83(93)94)74(130)111-54(26-10-14-34-86)71(127)114-59(32-20-40-101-84(95)96)75(131)112-55(27-11-15-35-87)72(128)115-60(33-21-41-102-85(97)98)76(132)116-61(81(137)138)29-13-17-37-89/h4-9,22-25,48-50,53-63,67,119-120H,10-21,26-47,86-90H2,1-3H3,(H,103,121)(H,104,126)(H,105,136)(H,106,122)(H,107,135)(H,108,123)(H,109,124)(H,110,125)(H,111,130)(H,112,131)(H,113,129)(H,114,127)(H,115,128)(H,116,132)(H,117,133)(H,118,134)(H,137,138)(H4,91,92,99)(H4,93,94,100)(H4,95,96,101)(H4,97,98,102)/t48-,49-,50+,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,67-/m0/s1
|
|||
| InChIKey |
UJJPEJMTOWTFSE-VDORGCAASA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Nociceptin receptor (OPRL1) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.